Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Specific binding of a hexanucleotide to HIV-1 reverse transcriptase: a novel class of bioactive molecules.

Mescalchin A, Wünsche W, Laufer SD, Grohmann D, Restle T, Sczakiel G.

Nucleic Acids Res. 2006;34(19):5631-7. Epub 2006 Oct 12.

2.

DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity.

Andreola ML, Pileur F, Calmels C, Ventura M, Tarrago-Litvak L, Toulmé JJ, Litvak S.

Biochemistry. 2001 Aug 28;40(34):10087-94.

PMID:
11513587
3.

Cross-linking of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase to template-primer.

Peletskaya EN, Boyer PL, Kogon AA, Clark P, Kroth H, Sayer JM, Jerina DM, Hughes SH.

J Virol. 2001 Oct;75(19):9435-45.

4.

De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.

Herschhorn A, Lerman L, Weitman M, Gleenberg IO, Nudelman A, Hizi A.

J Med Chem. 2007 May 17;50(10):2370-84. Epub 2007 Apr 26. Erratum in: J Med Chem. 2007 Jul 12;50(14):3402.

PMID:
17458947
5.

Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance.

Yamazaki S, Tan L, Mayer G, Hartig JS, Song JN, Reuter S, Restle T, Laufer SD, Grohmann D, Kräusslich HG, Bajorath J, Famulok M.

Chem Biol. 2007 Jul;14(7):804-12.

6.

Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.

Sweeney ZK, Harris SF, Arora SF, Javanbakht H, Li Y, Fretland J, Davidson JP, Billedeau JR, Gleason SK, Hirschfeld D, Kennedy-Smith JJ, Mirzadegan T, Roetz R, Smith M, Sperry S, Suh JM, Wu J, Tsing S, Villaseñor AG, Paul A, Su G, Heilek G, Hang JQ, Zhou AS, Jernelius JA, Zhang FJ, Klumpp K.

J Med Chem. 2008 Dec 11;51(23):7449-58. doi: 10.1021/jm800527x.

PMID:
19007201
7.

A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.

Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.

J Biol Chem. 2009 Jan 2;284(1):254-64. doi: 10.1074/jbc.M802199200. Epub 2008 Oct 23.

8.

3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.

San Juan AA.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1181-94. Epub 2007 Dec 8.

PMID:
18155520
9.

Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization.

Grohmann D, Corradi V, Elbasyouny M, Baude A, Horenkamp F, Laufer SD, Manetti F, Botta M, Restle T.

Chembiochem. 2008 Apr 14;9(6):916-22. doi: 10.1002/cbic.200700669.

PMID:
18318036
10.

HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity.

Kensch O, Connolly BA, Steinhoff HJ, McGregor A, Goody RS, Restle T.

J Biol Chem. 2000 Jun 16;275(24):18271-8.

11.

Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.

Li Z, Han J, Chen HF.

Chem Biol Drug Des. 2008 Nov;72(5):350-9. doi: 10.1111/j.1747-0285.2008.00713.x.

PMID:
19012571
12.

Novel HIV-1 reverse transcriptase inhibitors.

Jochmans D.

Virus Res. 2008 Jun;134(1-2):171-85. doi: 10.1016/j.virusres.2008.01.003. Epub 2008 Mar 4. Review.

PMID:
18308412
13.

Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.

Samuele A, Kataropoulou A, Viola M, Zanoli S, La Regina G, Piscitelli F, Silvestri R, Maga G.

Antiviral Res. 2009 Jan;81(1):47-55. doi: 10.1016/j.antiviral.2008.09.008. Epub 2008 Nov 5.

PMID:
18984007
14.
15.
16.

Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).

Lavecchia A, Costi R, Artico M, Miele G, Novellino E, Bergamini A, Crespan E, Maga G, Di Santo R.

ChemMedChem. 2006 Dec;1(12):1379-90.

PMID:
17089434
17.

Characterization of HIV-1 enzyme reverse transcriptase inhibition by the compound 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid through kinetic and in silico studies.

Souza TM, Rodrigues DQ, Ferreira VF, Marques IP, da Costa Santos F, Cunha AC, de Souza MC, de Palmer Paixão Frugulhetti IC, Bou-Habib DC, Fontes CF.

Curr HIV Res. 2009 May;7(3):327-35.

PMID:
19442130
18.

Properties of quadruplex oligonucleotides with anti-HIV-1 activity.

Tamura Y, Yoshida M, Suzuki J, Hiratou T, Miyano-Kurosaki N, Takai K, Takaku H.

Nucleic Acids Symp Ser. 2000;(44):181-2.

PMID:
12903328
19.

Novel methods of generating specific oligonucleotide inhibitors of viral polymerases.

Chen H, Brown D, Gold L.

Methods Enzymol. 1996;275:503-20. No abstract available.

PMID:
9026656
20.

Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.

Butini S, Brindisi M, Cosconati S, Marinelli L, Borrelli G, Coccone SS, Ramunno A, Campiani G, Novellino E, Zanoli S, Samuele A, Giorgi G, Bergamini A, Di Mattia M, Lalli S, Galletti B, Gemma S, Maga G.

J Med Chem. 2009 Feb 26;52(4):1224-8. doi: 10.1021/jm801395v.

PMID:
19170521

Supplemental Content

Support Center